Evidence map›Paper›PMID 10688882›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2000

Cyclic peptide formation catalyzed by an antibody ligase.

D B Smithrud, P A Benkovic, S J Benkovic, V Roberts, J Liu, I Neagu, S Iwama, B W Phillips, A B Smith, R Hirschmann

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 15 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

D B SmithrudDepartment of Chemistry, Pennsylvania State University, University Park, PA 16802, USA.
P A Benkovic
S J Benkovic
V Roberts
J Liu
I Neagu
S Iwama
B W Phillips
A B Smith
R Hirschmann
University of Pennsylvania · USScripps Research Institute · USPennsylvania State University · US

Funding

CATALYTIC ANTIBODIES FOR PEPTIDE SYNTHESISR01GM045611 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI HIRSCHMANN, RALPH F · 1991 to 1998
–
ANTIBODY STRUCTURE AND CATALYSIS BY DESIGNR29GM048877 · NIGMS · SCRIPPS RESEARCH INSTITUTE · PI ROBERTS, VICTORIA A · 1993 to 1997
–
NIGMS NIH HHS GM-45611NIGMS NIH HHS GM-48877
6 · The paper itself

Abstract

Cyclic hexapeptides represent a class of compounds with important, diverse biological activities. We report herein that the antibody 16G3 catalyzes the cyclization of d-Trp-Gly-Pal-Pro-Gly-Phe small middle dotp-nitrophenyl ester (8a) to give c-(d-Trp-Gly-Pal-Pro-Gly-l-Phe) (11a). The antibody does not, however, catalyze either epimerization or hydrolysis. The resulting rate enhancement of the cyclization by 16G3 (22-fold) was sufficient to form the desired product in greater than 90% yield. In absolute rate terms, the turnover of 16G3 is estimated to be 2 min(-1). The background rate of epimerization of 8a was reduced from 10 to 1% and hydrolysis from 50 to 4% in the presence of 16G3. As expected, the catalytic effects of 16G3 were blocked by the addition of an amount of the hapten equal to twice the antibody concentration. We also synthesized three diastereomers of 8a: the d-Trp(1)-d-Phe(6) (8b), l-Trp(1)-l-Phe(6) (8c), and l-Trp(1)-d-Phe(6) (8d) hexapeptides as well as d-Trp'-l-Trp(6) (12) and d-Phe'-l-Phe(6) (13). As expected, the rate enhancement by 16G3 was greatest for 8a, because the stereochemistry of Trp(1) and Phe(6) matches that of the corresponding residues on the hapten used to induce the biosynthesis of 16G3. A model of the variable domain of 16G3 was generated from the primary sequence using the antibody structural database to guide the model construction. The resulting model provided support for some previously proposed interpretations of the kinetic data, while providing valuable new insights for others.

Indexed as

Antibodies, CatalyticCatalysisEstersHaptensLigasesModels, MolecularMolecular StructurePeptides, CyclicAntibodies, CatalyticEstersHaptensLigasesPeptides, Cyclic

Identifiers

PMID10688882
PMCPMC15735
OpenAlexW2144887795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.